A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

NCT01130337 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Capecitabine [Xeloda]
DRUG: Oxaliplatin
DRUG: Trastuzumab [Herceptin]

Sponsor

Hoffmann-La Roche